A Phase I Study of GFH312 in Healthy Chinese Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: GFH312 200 mgDrug: GFH312 120mgOther: PlaceboDrug: GFH312 100 mg
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Zhejiang Genfleet Therapeutics Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT05991362
- Locations
- 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)
Phase 2
Withdrawn
- Conditions
- Intermittent ClaudicationPeripheral Artery Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Zhejiang Genfleet Therapeutics Co., Ltd.
- Registration Number
- NCT05618691
- Locations
- 🇺🇸
Midwest Cardiovascular Research Foundation, Davenport, Iowa, United States
A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Zhejiang Genfleet Therapeutics Co., Ltd.
- Registration Number
- NCT05165849
A Study of GFH018 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Zhejiang Genfleet Therapeutics Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT05051241
- Locations
- 🇨🇳
Shanghai East hospital, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath